Patrick Ferguson’s Post

Approximately 6.7 million Americans over 20 years old have #heartfailure, which is expected to rise to 8.5 million Americans by 2030. Join us at OM1, Inc. Feb 12-16th for Heart Failure week.  Pharma companies are paying anywhere from $75K to $5M per year to acquire datasets that can speed up drug discovery, clinical trial design, and regulatory reporting. Top 10 Pharma uses OM1’s Heart Failure (HF) dataset to drive insights from both observed and amplified endpoints such as LVEF and NYHA. OM1 helps to fill crucial gaps not readily available in RWD through extraction of clinical notes by machine learning and extraction. Including this information in the HF data set can greatly improve assessment of the patient journey and the evaluation of treatment outcomes in the HF patient population and within different clinical phenotypes. The estimation model for NYHA (eNYHA) has been validated and a methodology publication is in progress. Interested in learning more? 📍 https://lnkd.in/edaasdns #clinicaltrials #heartfailure #HFWeek2024 #hf

Beyond cardiac-specific therapies, every investigational drug has the potential to impact cardiac function, making QT monitoring a critical part of any drug development process. AliveCor’s medical-grade technology solution for cardiac safety empowers clinicians with real-time heart data while enabling patients to remotely participate in trials, improving engagement and compliance. Learn more:  https://lnkd.in/gVzNTtxm Also, check out our NEW BioPharma resources webpage for clinical research content, industry perspectives, key insights from experts, and more: https://lnkd.in/gBcEdGwb #ClinicalTrials #ClinicalResearch #ECG #CardiacMonitoring

Multiple Sclerosis Market Assessment 2034 | Multiple Sclerosis Therapies, FDA Approval, Clinical trials, Prevalence, Treatment Algorithms and Companies by DelveInsight | Immune Response BioPharma: Multiple Sclerosis Market As per DelveInsight, the Multiple Sclerosis Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Multiple Sclerosis in the 7MM. DelveInsight’s … Continue reading → #Business #Europe #HealthMedicine #PharmaceuticalsBiotech #US

We are grateful to Roche & Genentech for advancing the case for digital endpoints in clinical trials. SPITFIRE Trial post hoc analyses have revealed: 1️⃣ SV95C can detect changes in motor function faster than gold standards (6MWD, 4SC velocity, and NSAA). 2️⃣  SV95C is robust, reliable, and applicable to a broader population. 3️⃣ Syde is widely accepted by patients and is compatible with their lifestyles. Do you want to read the paper? The link to the paper in the comments below 👇

An indisputable fact in any Alzheimer's reasearch area is the importance of an early detection.

📢Join us for an insightful presentation by Dr Eva M Carmona Porquera at the 8th Annual IPF Summit. Here's a snapshot of what she will be covering. 🔹Failure of phase 3 clinical trials for IPF, despite promising phase 2 trials: what are the implications in making new drugs available for IPF? 🔹Understanding the different subgroups of IPF: how can this help to advance therapeutic options? 🔹FVC is an important endpoint for clinical trials but reliable and reproducible results are important to reconcile data from multicenter clinical trials. See you there! View the IPF Summit website here ➡️ https://hubs.ly/Q02LHQJQ0 #IPF #pulmonaryfibrosis #respiratorymedicine #clinicaltrials

#ESMOGynae24: The recent approval by the US FDA of pembrolizumab combined with chemoradiotherapy (CRT) for high-risk #CervicalCancer marks a significant advancement in treatment. But how applicable is this combination for low- and middle-income countries, where most of the global burden of #CervicalCancer lies? A subgroup analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial revealed that adding pembrolizumab to CRT reduced the risk of progression or death by 45% in East Asian patients. Despite these promising results, the cost of this combination therapy poses a significant challenge, with expenses varying widely between countries. 👇Read Ilaria Colombo's insights in the latest #ESMODailyReporter article https://ow.ly/Mwve50SmkGp

#health_equity means the attainment of the highest level of health for all people, where everyone has a fair and just opportunity to attain their optimal health regardless of race, ethnicity, disability, sexual orientation, gender identity, socioeconomic status, geography, and preferred language. While magnificent advances in the management of #patients suffering from #cancer have been introduced during the last decades and have improved the #survival_rates, most of these treatments are not easily available for patients from #developing countries...

Getting to grips with clinical trials: how can start-ups ensure bioanalyticalsis success? Tom Zhang, Worldwide Clinical Trials' CSO of Large Molecule Bioanalysis, details the need for bioanalytical and clinical expertise to meet assay requirements, and shares strategies for overcoming clinical trial bottlenecks >>> https://hubs.ly/Q02HM5-D0

We just published a research update on Immuron (ASX:IMC, A$0.073): Progressing fast with clinical trials. The company has made significant progress in recent months with clinical studies, the results of which will be published later in 2024. We reiterate our valuation of Immuron as first outlined in our initiation report – at A$0.25 per share in a base case scenario and A$0.35 per share in an optimistic (bull) case scenario. #immuron #asx